Altimmune announces common stock offering, no amount given

Altimmune (ALT) announced it has commenced an underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase an equivalent number of shares of its common stock, and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying common stock warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed public offering are being offered by Altimmune. Altimmune intends to use the net proceeds from this proposed offering to fund its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis, as well as for working capital and general corporate purposes. Leerink Partners and Barclays are acting as joint bookrunning managers for the proposed offering. Titan Partners is acting as co-bookrunning manager for the proposed offering.